ponatinib
chemical compound
≈ 1 min read
Names in other languages
- DeutschPonatinib
- Englishponatinib
- Françaisponatinib
- ItalianoPonatinib
- shPonatinib
- СрпскиPonatinib
- 简体中文ponatinib
- עבריתפונטיניב
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor.
Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. Ponatinib was approved for medical use in the United States in December 2012, and in the European Union in July 2013.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371079761 under CC BY-SA 4.0; modifications have been made.